

1/13

H₂N-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAI-CO₂H (SEQ ID NO: 1)
1 10 20 30 40

FIG. 1

H₂N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Cys-amide (SEQ ID NO: 2)
1 5 10 15

FIG. 2

Cys-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-amide (SEQ ID NO: 3)
10 15 20 25

FIG. 3

Cys-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr-CO₂H (SEQ ID NO: 4)
35 40

FIG. 4

FOOT-4652550




FIG. 5




FIG. 6




FIG. 7

T090T " 46626560




FIG. 8

5/13







FIG. 9






Transition-state




Phosphonate




Phosphoramidate

FIG. 11

8/13



Gly-Gly-PO₂⁻-NH-Val-Val



Gly-Gly-CO-NH-Val-Val

FIG. 12




FIG. 13




FIG. 14

11/13

Anti-A β Transition-state Antibodies Plus 125 I-A β -Sephacose





FIG. 15

12/13



Receptor-Positive Cells

FIG. 16




FIG. 17